CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.

CVS Health Corporation CVS is scheduled to report second-quarter 2025 results on July 31, before the opening bell. In the ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

The California Public Employees’ Retirement System (CalPERS) has a new pharmacy benefits contract with CVS Caremark, the ...

The contract, though sizable, is likely immaterial to CVS’ earnings. But it moves the company in a positive direction as it ...

CVS Health's pharmacy benefit manager unit must pay the U.S. government $95 million after a federal judge found it overcharged Medicare for prescription drugs.

Just before President Trump pushed her out at the behest of his corporate donors, former Federal Trade Commission chairwoman Lina Khan released a damning report about the most rapacious and ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

CVS Health’s Caremark business signed a new pharmacy benefits contract with the California Public Employees’ Retirement ...

As of July 1, CVS dropped Zepbound from preferred coverage for those covered by its pharmacy benefit manager, Caremark. Novo Nordisk A/S's Wegovy, a semiglutide injectable medicine, is now the primary ...

CVS Caremark stops coverage for Eli Lilly's weight loss drug Zepbound, citing high costs, while obesity specialists warn the decision disrupts patient treatment.

Pharmacy benefit manager CVS Caremark decided to replace Zepbound with Wegovy for use in weight loss starting July 1, despite Zepbound users having more weight loss success.